Compare PBHC & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | ONCY |
|---|---|---|
| Founded | 1859 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.9M | 107.3M |
| IPO Year | 2014 | 2002 |
| Metric | PBHC | ONCY |
|---|---|---|
| Price | $16.15 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 18.0K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 46.25 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $0.77 |
| 52 Week High | $17.40 | $1.51 |
| Indicator | PBHC | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 40.45 |
| Support Level | $15.05 | N/A |
| Resistance Level | $17.11 | $1.06 |
| Average True Range (ATR) | 0.69 | 0.07 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 33.26 | 3.49 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.